New Drug Development: A Regulatory Overview
Third Edition

by
Mark Mathieu

with contributions from
Anne G. Evans, D.V.M.
and
Eric L. Hurden, M.Sc., Ph.D.

PAREXEL International Corporation
Waltham, MA
Publishers
# Contents

Chapter 1: The New Drug Approval Process: A Primer .................................1
Chapter 2: Nonclinical Drug Testing ..........................................................15
Chapter 3: FDA Standards for Nonclinical Testing: Good Laboratory Practice (GLP) ..............................................................35
Chapter 4: The Investigational New Drug Application (IND) ....................45
Chapter 5: CDER and the IND Review Process .......................................75
Chapter 6: The Clinical Development of New Drugs ...............................101
Chapter 7: Good Clinical Practices (GCP) .................................................129
Chapter 8: The New Drug Application (NDA) .........................................145
Chapter 9: The NDA Review Process .........................................................179
Chapter 10: The FDA’s Drug Classification System .................................207
Chapter 11: Advisory Committees and the Drug Approval Process ..........215
Chapter 12: The FDA’s Drug Listing and Establishment Registration Requirements ..........................................................229
Chapter 13: Beyond Approval: Drug Manufacturer Regulatory Responsibilities ..........................................................235
Chapter 14: The Supplemental NDA .........................................................251
Chapter 15: The FDA’s Orphan Drug Development Program ....................261
Chapter 16: CDER’s Bioresearch Monitoring Program ............................273
Chapter 17: Accelerated Drug Approval/Accessibility Programs ..............285
Chapter 18: The FDA’s Prescription Drug User Fee Program ..................303
Chapter 19: FDA Initiatives to Speed Drug Reviews ...............................313
Index ........................................................................................................323